

**SEP 26 2000**

**510(k) Summary for  
BN ProSpec™ System**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K001647

**1. Manufacture's Name, Address, Telephone, and Contact Person, Date of Preparation:**

Manufacturer: Dade Behring Marburg GmbH  
Emil-von-Behring Str. 76  
Marburg/Germany

Contact Information: Dade Behring Inc.  
Glasgow Site  
P.O. Box 6101  
Newark, Delaware 19714  
Attn: Rebecca S. Ayash

Preparation date: May 26, 2000

**2. Device Name/ Classification:**

BN ProSpec™ System: Immunonephelometer Equipment

Classification Number: Class I (866.4540)

**3. Identification of the Legally Marketed Device:**

Dade Behring BN II™ System [K943997]

**4. Device Description:**

The BN ProSpec™ System is a nephelometer for clinical use intended to determine the concentration of antigen-antibody complexes in a suspension by measuring their light scattering properties (the deflection of light rays by opaque particles in their path). The BN ProSpec™ System is used in conjunction with Dade Behring reagents to measure the concentration of a variety of analytes.



DEPARTMENT OF HEALTH & HUMAN SERVICES

SEP 26 2000

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Rebecca S. Ayash  
Manager, Regulatory Affairs, Biology  
Dade Behring, Inc.  
Glasgow Site  
P.O. Box 6101  
Newark, Delaware 19714

Re: K001647  
Trade Name: BN ProSpec™ System  
Regulatory Class: I  
Product Code: JZW  
Dated: August 22, 2000  
Received: August 23, 2000

Dear Ms. Ayash:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.


A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure


K001647

### Indications Statement

Device Name: BN ProSpec™ System

#### Indications for Use:

The BN ProSpec™ is an automated nephelometer analyzer for *in vitro* diagnostic use in clinical laboratories. The BN ProSpec™ System is intended to determine the concentration of antigen-antibody complexes in a suspension by measuring their light scattering properties (the deflection of light rays by opaque particles in their path). The BN ProSpec™ System is used in conjunction with Dade Behring reagents to measure the concentration of a variety of analytes.

  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K001647

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒  
(Per 21 CFR 801.109)

Over-The-Counter-Use ☐  
(Optional Format 1-2-96)